Pazopanib (PZP) in germ cell tumors (GCT) after chemotherapy (CT) failure: Final results of the open label, single-group, phase II Pazotest trial.

被引：0
|
作者：
Necchi, Andrea
Lo Vullo, Salvatore
Giannatempo, Patrizia
Raggi, Daniele
Calareso, Giuseppina
Togliardi, Elena
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.414
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
414
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pazopanib in chemoresistant patients with germ cell tumors (GCT): Updated results of the open-label, single-group, phase 2 Pazotest-01 trial.
    Glennatempo, Patrizia
    Mariani, Luigi
    Nicolai, Nicola
    Fare, Elena
    Raggi, Daniele
    Maronglu, Manuals
    Plva, Luigi
    Blasonl, Davide
    Catanzaro, Mario
    Torelli, Tullio
    Stagni, Silvia
    Maffezzini, Massimo
    Togliardi, Elena
    Salvioni, Roberto
    De Braud, Filippo G.
    Gianni, Alessandro M.
    Necchi, Andrea
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] PAZOPANIB IN CHEMORESISTANT PATIENTS WITH GERM CELL TUMORS (GCT): UPDATED RESULTS OF THE OPEN-LABEL, SINGLE-GROUP, PHASE 2 PAZOTEST-01 TRIAL
    Necchi, Andrea
    Giannaternpo, Patrizia
    Mariani, Luigi
    Nicolai, Nicola
    Fare, Elena
    Raggi, Daniele
    Piva, Luigi
    Biasoni, Davide
    Catanzaro, Mario
    Torelli, Tullio
    Stagni, Silvia
    Maffezzini, Massimo
    Togliardi, Elena
    Salvioni, Roberto
    De Braud, Filippo
    Gianni, Alessandro
    [J]. ANTICANCER RESEARCH, 2014, 34 (05) : 2661 - 2662
  • [3] Pazopanib in patients (pts) with advanced germ cell tumors (GCT): Results from an open-label, single-group, phase 2 trial (Pazotest-01).
    Necchi, Andrea
    Raggi, Daniele
    Giannatempo, Patrizia
    Calareso, Giuseppina
    Togliardi, Elena
    Nicolai, Nicola
    Crippa, Flavio
    Mariani, Luigi
    Salvioni, Roberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [4] Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial
    Giannatempo, Patrizia
    Nicolai, Nicola
    Fare, Elena
    Raggi, Daniele
    Piva, Luigi
    Biasoni, Davide
    Catanzaro, Mario
    Torelli, Tullio
    Stagni, Silvia
    Maffezzini, Massimo
    Crestani, Alessandro
    Togliardi, Elena
    Salvioni, Roberto
    Gianni, Alessandro M.
    Necchi, Andrea
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [5] Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial
    Necchi, A.
    Lo Vullo, S.
    Giannatempo, P.
    Raggi, D.
    Calareso, G.
    Togliardi, E.
    Crippa, F.
    Pennati, M.
    Zaffaroni, N.
    Perrone, F.
    Busico, A.
    Colecchia, M.
    Nicolai, N.
    Mariani, L.
    Salvioni, R.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (06) : 1346 - 1351
  • [6] Olaparib as salvage treatment for advanced germ cell tumors after chemotherapy failure: Results of the open-label, single-arm, IGG-02 phase II trial.
    De Giorgi, Ugo
    Schepisi, Giuseppe
    Gurioli, Giorgia
    Pisano, Carmela
    Basso, Umberto
    Lolli, Cristian
    Petracci, Elisabetta
    Casadei, Chiara
    Cecere, Sabrina Chiara
    Attademo, Laura
    Clemente, Alberto
    Zampiga, Valentina
    Galla, Valentina
    Cangini, Ilaria
    Di Napoli, Marilena
    Valmorri, Linda
    Pignata, Sandro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01).
    Necchi, Andrea
    Magazzu, Domenico
    Anichini, Andrea
    Raggi, Daniele
    Giannatempo, Patrizia
    Nicolai, Nicola
    Colecchia, Maurizio
    Paolini, Biagio
    Coradeschi, Elisa
    Tassi, Elena
    Grazia, Giulia
    Mortarini, Roberta
    Calareso, Giuseppina
    Togliardi, Elena
    Crippa, Flavio
    Salvioni, Roberto
    Gianni, Alessandro M.
    Valagussa, Pinuccia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [8] An open-label, single-group, phase 2 study of Brentuximab Vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): results at the end of first stage (FM12GCT01)
    Necchi, A.
    Magazzu, D.
    Anichini, A.
    Raggi, D.
    Giannatempo, P.
    Colecchia, M.
    Coradeschi, E.
    Calareso, G.
    Togliardi, E.
    Crippa, F.
    Salvioni, R.
    Valagussa, P.
    [J]. BONE MARROW TRANSPLANTATION, 2016, 51 : S56 - S56
  • [9] Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
    Kaufman, Howard L.
    Russell, Jeffery
    Hamid, Omid
    Bhatia, Shailender
    Terheyden, Patrick
    D'Angelo, Sandra P.
    Shih, Kent C.
    Lebbe, Celeste
    Linette, Gerald P.
    Milella, Michele
    Brownell, Isaac
    Lewis, Karl D.
    Lorch, Jochen H.
    Chin, Kevin
    Mahnke, Lisa
    von Heydebreck, Anja
    Cuillerot, Jean-Marie
    Nghiem, Paul
    [J]. LANCET ONCOLOGY, 2016, 17 (10): : 1374 - 1385
  • [10] Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT).
    Nieto, Yago
    Tannir, Nizar M.
    Tu, Shi-Ming
    Jones, Roy B.
    Zurita, Amado J.
    Aparicio, Ana
    Bassett, Roland
    Margolin, Kim Allyson
    Holmberg, Leona
    Champlin, Richard E.
    Pagliaro, Lance C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345